{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+Tablets", "query": { "intervention": "Ezetimibe Tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+Tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T19:03:11.259Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06050291", "title": "Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer Study" ], "interventions": [ { "name": "Fixed-Dose Combination (FDC) Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 28, "start_date": "2024-01-20", "completion_date": "2024-04-07", "has_results": false, "last_update_posted_date": "2024-06-05", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06050291" }, { "nct_id": "NCT06005597", "title": "Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemias", "Hypercholesterolemia", "Familial Hypercholesterolemia", "ASCVD", "High Cholesterol" ], "interventions": [ { "name": "Combination Therapy", "type": "COMBINATION_PRODUCT" }, { "name": "Monotherapy obicetrapib", "type": "DRUG" }, { "name": "Monotherapy ezetimibe", "type": "DRUG" }, { "name": "Combination Therapy placebo", "type": "OTHER" }, { "name": "Obicetrapib Placebo", "type": "OTHER" }, { "name": "Ezetimibe Placebo", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2024-03-01", "completion_date": "2024-10-16", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 45, "location_summary": "Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005597" }, { "nct_id": "NCT06742853", "title": "A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "AZD0780", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Bempedoic Acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 81, "start_date": "2024-12-20", "completion_date": "2025-10-29", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742853" }, { "nct_id": "NCT01709513", "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2012-09-30", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 41, "location_summary": "Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709513" }, { "nct_id": "NCT03337308", "title": "A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemias" ], "interventions": [ { "name": "Bempedoic Acid + Ezetimibe Fixed-Dose Combination", "type": "COMBINATION_PRODUCT" }, { "name": "Bempedoic Acid", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 382, "start_date": "2017-10-23", "completion_date": "2018-07-18", "has_results": true, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 5, "location_summary": "Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more", "locations": [ { "city": "Ames", "state": "Iowa" }, { "city": "Nashua", "state": "New Hampshire" }, { "city": "Statesville", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03337308" }, { "nct_id": "NCT00762164", "title": "Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Vytorin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bronx VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00762164" }, { "nct_id": "NCT02642159", "title": "Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Statins", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" }, { "name": "Nicotinic acid", "type": "DRUG" }, { "name": "Omega-3 fatty acids", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 413, "start_date": "2016-03-15", "completion_date": "2017-05-15", "has_results": true, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 57, "location_summary": "Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02642159" }, { "nct_id": "NCT01766713", "title": "Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Alcoholic Steatohepatitis" ], "interventions": [ { "name": "Ezetimibe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 50, "start_date": "2013-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01766713" }, { "nct_id": "NCT01644474", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for Alirocumab)", "type": "DRUG" }, { "name": "Placebo (for Ezetimibe)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2012-07", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 3, "location_summary": "Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644474" }, { "nct_id": "NCT03001076", "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia", "Atherosclerosis", "Statin Adverse Reaction" ], "interventions": [ { "name": "Bempedoic acid", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 269, "start_date": "2016-11-29", "completion_date": "2018-02-12", "has_results": true, "last_update_posted_date": "2020-05-11", "last_synced_at": "2026-09-02T19:03:11.259Z", "location_count": 1, "location_summary": "Georgetown, Texas", "locations": [ { "city": "Georgetown", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001076" } ] }